Welcome to our dedicated page for 23andMe Holding Co. news (Ticker: $ME), a resource for investors and traders seeking the latest updates and insights on 23andMe Holding Co. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 23andMe Holding Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 23andMe Holding Co.'s position in the market.
Rhea-AI Summary
23andMe (NASDAQ: ME) experienced a significant data breach, affecting over 4 million users. The breach compromised personal information, including names, birth years, email addresses, genetic ancestry, potential relatives, and geolocation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
-
Rhea-AI Summary
23andMe (ME) suffered a massive data leak, compromising personal information of over 4 million users. The attack targeted data such as full name, birth year, email address, genetic ancestry, potential relatives, and geolocation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
-
Rhea-AI Summary
23andMe Holding Co. (Nasdaq: ME) announces the expansion of the ongoing 23ME-00610 Phase 1/2a study to include 30 additional patients with advanced neuroendocrine and ovarian cancer. The study aims to evaluate the investigational antibody targeting CD200R1 and identify the optimal dose in alignment with recently published regulatory guidance. The ongoing study has shown appropriate safety profile and met pharmacodynamic biomarker and pharmacokinetic objectives. The Phase 2a portion of the study is being conducted with the highest tested dose from the Phase 1, and a second potentially efficacious dose will be evaluated in these additional patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.54%
Tags
Rhea-AI Summary
23andMe (ME) Announces Launch of 23andMe+ Total Health™ Membership and $20M Data License with GSK, Reports Q2 FY24 Financial Results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.98%
Tags
-
Rhea-AI Summary
23andMe Holding Co. (Nasdaq: ME) has launched 23andMe+ Total Health, a comprehensive prevention-based health membership that includes clinical grade exome sequencing, biannual blood testing, and access to genetics-based clinical care, aiming to help individuals understand and benefit from their genetic information for disease prevention and early detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
-
Rhea-AI Summary
23andMe presented data from its Phase 1/2a clinical trial of 23ME-00610, an investigational antibody targeting CD200R1. The data showed tolerability, preliminary efficacy, and a stable disease rate of 52% in patients with advanced solid tumors. No dose-limiting toxicities or serious adverse events were observed, and no maximum tolerated dose was reached. The Phase 2a portion of the study is currently enrolling and will assess objective response rate, progression-free survival, and overall survival in various expansion cohorts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.72%
Tags
Rhea-AI Summary
23andMe Holding Co. (ME) launches Health Action Plan, a new digital tool for 23andMe+ members. The tool provides customized action plans, lifestyle changes, and clinician-ordered lab tests based on genetic reports, health history survey data, and blood/biomarker data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.72%
Tags
-
Rhea-AI Summary
23andMe and GSK have extended their collaboration through a new non-exclusive data licensing agreement. GSK will utilize the 23andMe database for drug target discovery and other research. 23andMe will receive a $20 million upfront payment for the one-year license.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
-
Rhea-AI Summary
23andMe Holding Co. will report financial results for FY2024 Q2 on November 8, 2023. A conference call will be held to discuss the quarter's financial results and business progress. Shareholders can submit questions in advance through the Say Technologies platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
Rhea-AI Summary
23andMe to present data on efficacy and safety of ongoing clinical trial at SITC Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
23andMe Holding Co.
Nasdaq:ME
ME Rankings
ME Stock Data
240.30M
312.08M
3.94%
43.11%
6.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
SOUTH SAN FRANCISCO
About ME
23andme is the leading personal genetics company dedicated to helping individuals understand their own genetic information through dna analysis technologies and web-based interactive tools. the company's personal genome service® enables individuals to gain deeper insights into their ancestry and genetic make-up. the vision for 23andme is to personalize healthcare by making and supporting meaningful discoveries through genetic research. 23andme was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science.